TuHURA BIOSCIENCES, INC./NV Increase (Decrease) in Notes Payable, Related Parties, Current
TuHURA BIOSCIENCES, INC./NV (HURA) reported Increase (Decrease) in Notes Payable, Related Parties, Current of $2.97 thousand for the 3-month period ending 2012-09-30, per its 10-Q/A filed 2012-12-20.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent · last filed 2012-12-20
- TuHURA BIOSCIENCES, INC./NV increase (decrease) in notes payable, related parties, current for the quarter ending 2012-09-30 was $2.97K.
- TuHURA BIOSCIENCES, INC./NV increase (decrease) in notes payable, related parties, current for the quarter ending 2011-09-30 was $0.00.
| Period end | Increase (Decrease) in Notes Payable, Related Parties, Current 3 month | Increase (Decrease) in Notes Payable, Related Parties, Current 9 month | Increase (Decrease) in Notes Payable, Related Parties, Current 33 month | Increase (Decrease) in Notes Payable, Related Parties, Current 39 month |
|---|---|---|---|---|
| 2012-09-30 | $2.97K 10-Q/A · filed 2012-12-20 | $10.45K 10-Q/A · filed 2012-12-20 | ||
| 2012-03-31 | $7.48K 10-Q/A · filed 2012-06-05 | $7.48K 10-Q/A · filed 2012-06-05 | ||
| 2011-09-30 | $0.00 10-Q/A · filed 2012-12-20 | |||
| 2011-03-31 | $0.00 10-Q/A · filed 2012-06-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |